Elanco Animal Health Inc. — Q2 2022 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2022. Elanco develops, manufactures and sells animal health products for pets and farm animals in more than 90 countries. Figures are in U.S. dollars; financial statement amounts are in millions unless noted.
Financial performance and position
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $1,177 | $1,279 | $2,402 | $2,521 |
| Net income (loss) | $(22) | $(210) | $26 | $(271) |
| Diluted EPS | $(0.04) | $(0.43) | $0.05 | $(0.56) |
| Cost of sales as % of revenue | 41% | 43% | 41% | 44% |
| Interest expense | $67 | $60 | $119 | $121 |
- Revenue mix: Q2 Pet Health revenue was $612 million, down 11% (down 7% at constant exchange rates); Farm Animal revenue was $553 million, down 2% reported but up 3% at constant exchange rates. For the first half, Pet Health declined 6% reported and Farm Animal declined 2%.
- Margins and costs: Gross margin was approximately 59% in Q2 versus 57% a year earlier, based on reported cost of sales. Management cited manufacturing productivity, pricing and currency effects as favorable, partly offset by product mix and inflation in inputs, freight and conversion costs. R&D and marketing, selling and administrative expenses fell year over year.
- Cash flow: First-half operating cash flow was $250 million versus $171 million; investing cash outflow was $66 million and financing cash outflow was $296 million. Cash declined $131 million from year-end to $507 million. Operating cash flow included $132 million of interest-rate-swap settlement proceeds.
- Debt and liquidity: June 30 cash was $507 million; total debt carrying value was $6.063 billion, including $56 million current. Current assets were $3.307 billion and current liabilities $1.338 billion. Elanco reported compliance with all debt covenants. It issued $425 million of incremental term debt and retired $406 million principal of 2023 notes, recording a $17 million extinguishment loss.
- Other balance-sheet items: Goodwill was $5.898 billion and net intangible assets were $5.059 billion at June 30. Total assets were $15.601 billion and equity was $7.140 billion.
Material changes versus the prior comparable period
- Q2 revenue fell $102 million, or 8%; first-half revenue fell $119 million, or 5%. Currency reduced first-half revenue by 4%. Lower U.S. parasiticide volumes, including older-generation products, supply disruptions and competition weighed on Pet Health. Farm Animal performance reflected foreign-exchange pressure and weak swine demand, partly offset by ruminant demand and other growth.
- Net losses narrowed substantially in Q2 and the first half, while the first half returned to positive net income. The main year-over-year reduction in special charges included the absence of the prior-year $265 million write-down for the Shawnee and Speke sites.
- First-half special charges were $132 million, including a $59 million write-off of licensed BexCaFe in-process R&D and a $28 million Speke asset write-down. Q2 charges also included the $59 million BexCaFe expense.
- Foreign-currency translation losses contributed to first-half other comprehensive loss of $440 million. The company received $132 million from restructuring interest-rate swaps; the gain is being reclassified to interest expense over the related periods.
Outlook, commentary and risks
- The filing provides no numerical full-year revenue or earnings guidance. Management said liquidity sources were sufficient for planned requirements and expected covenant compliance, while noting that economic volatility could affect liquidity and access to financing.
- Management cited continuing supply-chain disruption, raw-material shortages, labor constraints, higher freight and input costs, inflation, foreign-exchange movements, and the uncertain effects of COVID-19 and the Russia-Ukraine conflict. Russian and Ukrainian customer revenue was about 1% of first-half consolidated revenue.
- Competitive pressure, generic products, distributor inventory fluctuations, product concentration, regulatory changes and execution of acquisition integration and cost-savings plans are material business risks. Pet Health sales are seasonal.
- Legal and regulatory matters: Elanco is defending shareholder litigation and Seresto collar-related lawsuits. A congressional subcommittee renewed calls for a Seresto recall and requested EPA action; the EPA was considering a petition to cancel the product registration. Elanco disputed the safety allegations and reported no material litigation liabilities accrued. The SEC had subpoenaed information concerning pre-mid-2020 channel inventory and sales practices; Elanco said it was cooperating.
- Other commitments: A new Indianapolis headquarters lease is expected to begin in 2024, with estimated minimum payments of approximately $310 million over 25 years, excluding extensions. The filing says final payments may vary with construction costs.
Most important facts for investors to verify
- Whether Pet Health volumes and supply constraints improve, and whether Farm Animal demand—particularly in swine—stabilizes.
- How much reported revenue and earnings are affected by foreign exchange, inflation, product mix and distributor inventory changes.
- Whether operating cash generation excluding the $132 million swap settlement supports debt service and integration needs; also monitor variable-rate debt and refinancing requirements.
- Developments in the Seresto litigation, congressional scrutiny and EPA petition, as well as the SEC inquiry and shareholder lawsuits.
- The ultimate costs and timing of acquisition integration, restructuring, the headquarters commitment and other contingent obligations.